Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
3
Neutral
6
Bullish
5
Bearish
23
Neutral
6
Bullish
17
Bearish
20
Neutral
0
Bullish
12
Discovery themes featuring this stock
Chandan Healthcare Limited operates an integrated diagnostics, radiology and retail pharmacy network primarily across North and Central India, running company-owned labs and diagnostic centres with NABL/NABH accreditations and a digital front-end called Chandan 24x7 for appointments, e-pharmacy and patient records.
In Q3 FY26 Chandan reported consolidated Total Income of ₹65.77 crore (up ~20% YoY) and EBITDA of ₹12.61 crore with a 263 bps expansion in EBITDA margin to 19.17%; nine‑month results show sustained improvement with 9M FY26 Total Income ₹203.27 crore and EBITDA margin rising to 20.95%.
The company has completed a preferential issuance raising ~₹104.13 crore (44,50,000 warrants at ₹234 each) with participation from promoter and strategic investors; proceeds are earmarked for ₹44.50 crore of expansion capex and ₹50 crore for acquisitions, materially funding the three‑year roll-out plan.
Chandan is aggressively scaling: target to build ~100 labs across 17 states and onboard 1,000 franchise collection points in three years, while already securing a large multi‑year government PPP radiology contract in Punjab and an exclusive five‑year diagnostics tie-up with Jeena Sikho Lifecare that provides meaningful recurring volumes.
Customer engagement levers include a loyalty programme with 40 lakh+ cardholders and a digital app with 100k+ downloads; complementary pharmacy revenues (~46% of FY25 revenue) provide cross‑sell opportunities and improved lifetime value in target Tier 2/3 markets where Chandan emphasises affordability and local leadership.
Healthcare Services
Healthcare Service Provider
622 Cr
Moderate Risk
22.9
56.7
0.5
4.5
358.00
150.30
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
538.40 | 1,044 Cr | 21.47 | 10.31 | 0.00 | 43.51 | 58.07 | 27.58 | ||
78.20 | 886 Cr | 25.06 | 5.95 | 0.00 | 55.85 | 55.95 | 21.30 | ||
269.00 | 881 Cr | 32.89 | 1.29 | 0.00 | -0.30 | -4.66 | 2.89 | ||
248.20 | 622 Cr | 23.02 | 4.50 | 0.00 | 18.69 | 20.84 | 10.52 | ||
248.25 | 268 Cr | 42.73 | 4.28 | 0.00 | 13.28 | 18.53 | 9.99 | ||
67.05 | 194 Cr | 17.46 | 3.76 | 0.00 | 11.99 | 14.14 | 7.06 | ||
58.25 | 143 Cr | 24.47 | 2.67 | 0.00 | 6.13 | 8.59 | 5.07 | ||
| Median: 7 Co. | — | 248.20 | 622 Cr | 24.47 | 4.28 | 0.00 | 13.28 | 18.53 | 9.99 |
Chandan Healthcare Ltd (CHANDAN) is currently trading at 255.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Chandan Healthcare Limited operates an integrated diagnostics, radiology and retail pharmacy network primarily across North and Central India, running company-owned labs and diagnostic centres with NABL/NABH accreditations and a digital front-end called Chandan 24x7 for appointments, e-pharmacy and patient records. In Q3 FY26 Chandan reported consolidated Total Income of ₹65.77 crore (up ~20% YoY) and EBITDA of ₹12.61 crore with a 263 bps expansion in EBITDA margin to 19.17%; nine‑month results show sustained improvement with 9M FY26 Total Income ₹203.27 crore and EBITDA margin rising to 20.95%. The company has completed a preferential issuance raising ~₹104.13 crore (44,50,000 warrants at ₹234 each) with participation from promoter and strategic investors; proceeds are earmarked for ₹44.50 crore of expansion capex and ₹50 crore for acquisitions, materially funding the three‑year roll-out plan. Chandan is aggressively scaling: target to build ~100 labs across 17 states and onboard 1,000 franchise collection points in three years, while already securing a large multi‑year government PPP radiology contract in Punjab and an exclusive five‑year diagnostics tie-up with Jeena Sikho Lifecare that provides meaningful recurring volumes. Customer engagement levers include a loyalty programme with 40 lakh+ cardholders and a digital app with 100k+ downloads; complementary pharmacy revenues (~46% of FY25 revenue) provide cross‑sell opportunities and improved lifetime value in target Tier 2/3 markets where Chandan emphasises affordability and local leadership.
Over the past 52 weeks, Chandan Healthcare Ltd has traded between a low of ₹150.30 and a high of ₹358.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Chandan Healthcare Ltd has a market capitalization of approximately 622.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Chandan Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.93 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 622.06 Cr, Chandan Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Chandan Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Chandan Healthcare Ltd is 22.93. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
